Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.56 |
| ▸ | CA1 | P00915 | 5/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2672026 | 1.00 | CA2 (0.56) | CA2CA1CA9CA12CA4 | |
| SCHEMBL2672023 | 0.95 | CA2 (0.60) | CA2CA1CA9CA12CA4 | |
| SCHEMBL1705397 | 0.93 | CA1 (0.54) | CA2CA1CA9CA12CA4 | |
| SCHEMBL2671393 | 0.93 | CA1 (0.54) | CA2CA1CA9CA12CA4 | |
| SCHEMBL1705396 | 0.91 | CA2 (0.58) | CA2CA1CA9CA12CA4 | |
| SCHEMBL10204186 | 0.89 | CA2 (0.57) | CA2CA1CA9CA12CA4 | |
| SCHEMBL10204170 | 0.87 | CA2 (0.59) | CA2CA1CA9CA12CA4 | |
| SCHEMBL11520537 | 0.86 | CA2 (0.58) | CA2CA1CA9CA12CA4 | |
| SCHEMBL15254186 | 0.85 | CA2 (0.63) | CA2CA1CA9CA12CA4 | |
| SCHEMBL15254188 | 0.85 | CA2 (0.63) | CA2CA1CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108501-A1 | Protease Inhibitors | NEKTAR THERAPEUTICS (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2010144869-A2 | PROTEASE INHIBITORS | NEKTAR THERAPEUTICS (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108501-A1 | Protease Inhibitors | DNPEP, ADAM17, PREP | CA2 2148/4885CA1 1106/4885CA9 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.